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Damaged DNA binding protein 1, DDB1, bridges an estimated 90 or more WD40 repeats (DDB1-binding
WD40, or DWD proteins) to the CUL4-ROC1 catalytic core to constitute a potentially large number of E3 ligase
complexes. Among these DWD proteins is the human immunodeficiency virus type 1 (HIV-1) Vpr-binding
protein VprBP, whose cellular function has yet to be characterized but has recently been found to mediate
Vpr-induced G2 cell cycle arrest. We demonstrate here that VprBP binds stoichiometrically with DDB1 through
its WD40 domain and through DDB1 to CUL4A, subunits of the COP9/signalsome, and DDA1. The steady-state
level of VprBP remains constant during interphase and decreases during mitosis. VprBP binds to chromatin
in a DDB1-independent and cell cycle-dependent manner, increasing from early S through G2 before decreas-
ing to undetectable levels in mitotic and G1 cells. Silencing VprBP reduced the rate of DNA replication, blocked
cells from progressing through the S phase, and inhibited proliferation. VprBP ablation in mice results in early
embryonic lethality. Conditional deletion of the VprBP gene in mouse embryonic fibroblasts results in severely
defective progression through S phase and subsequent apoptosis. Our studies identify a previously unknown
function of VprBP in S-phase progression and suggest the possibility that HIV-1 Vpr may divert an ongoing
chromosomal replication activity to facilitate viral replication.
Ubiquitin ligases play a critical role in cellular function by
recruiting various protein substrates for covalent modification
by the small protein ubiquitin (15, 31). Ubiquitin modification,
either monomeric or in polyubiquitin chains, leads to various
changes in cellular protein function, most prominently the
targeting of polyubiquitin-conjugated proteins to the 26S pro-
teasome for proteolytic degradation. The cullin family of ubiq-
uitin ligases performs remarkably broad functions due to their
ability to assemble a large number of distinct cullin-RING E3
ligase complexes through modular interaction with substrate
receptors containing specific protein-protein interaction motifs
(29). Cullins interact with their substrate receptors either di-
rectly, as in the case of CUL3, which interacts with one of more
than 200 BTB domain-containing receptors (10, 11, 32, 43), or
indirectly through a conserved linker protein, such as the SKP1
protein that bridges one of more than 70 F-box-containing
receptors to CUL1 (2, 9, 36) and the heterodimer of elongins
B and C that links one of the more than 30 VHL-box or
SOCS-box receptors with CUL2 or CUL5 (21, 22, 38, 44).
Through interaction with these common motifs, the cullin-
RING E3 ligase complexes may potentially ubiquitinate a large
number of substrates.
We along with other groups recently discovered that dam-
aged DNA binding protein 1, DDB1, acts a linker protein for
CUL4 and recruits substrates through interaction with a subset
of WD40 proteins (1, 14, 16, 19). Mammalian cells contain at
least 90 DDB1-binding WD40 (DWD) proteins (also known as
DCAF for Ddb1- and Cul4-associated factors and CDW for
CUL4 and DDB1-associated WD40 repeats), suggesting that
CUL4-ROC1 ligases may also promote ubiquitination of a
large number of substrates. One of the more than 30 mamma-
lian DWD proteins that have been experimentally demon-
strated to bind DDB1-CUL4 is VprBP/DCAF1 (accession
number NM014703), a 170-kDa protein that was initially iden-
tified through coimmunoprecipitation and peptide sequencing
of HIV-1 Vpr-binding proteins (VprBPs) (45). Very recently, it
has been shown that VprBP is required for the G2 cell cycle
arrest caused by Vpr expression (3, 8, 17, 24, 35, 39, 42). The
physiological significance underlying the Vpr-VprBP interac-
tion for human immunodeficiency virus (HIV) viral propaga-
tion remains unclear. VprBP orthologs are found in Drosophila
melanogaster (36% identical to human VprBP), Caenorhabditis
elegans (31%), and Arabidopsis thaliana (27%), but no obvious
ortholog is recognizable in yeast cells. VprBP is broadly ex-
pressed in most, if not all, human and mouse tissues that have
been examined (45). These features suggest an unknown but
conserved and possibly critical function of VprBP in multicel-
lular organisms. This study is directed toward elucidating this
issue.
MATERIALS AND METHODS
Antibodies, immunopurification, and mass spectrometric analysis. Antibodies
to hemagglutinin ([HA] 12CA5; Boehringer-Mannheim), Myc (9E10; NeoMarkers),
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T7 (Novagen), FLAG (M2; Sigma), p53 (DO-1; NeoMarkers), p21 (Neo-
Markers), histone H3 (Abcam), alpha-tubulin (NeoMarkers), MCM2 (B58720;
Transduction Laboratories), ORC2 (559266; BD Pharmagen), and CSN5 (JAB1;
GeneTex) were purchased commercially. Rabbit polyclonal antibodies to
CUL4A, DDB1, and CDT1 have been described previously (18). A rabbit poly-
clonal antibody against VprBP was produced by injection of a synthetic peptide
antigen into residues 1493 to 1507 of VprBP (DNSDLEDDIILSLNE). To purify
the endogenous CUL4A complex, BT474 cells from 47 150-mm plates were lysed
with a 0.5% NP-40 lysis buffer (50 mM Tris-HCl at pH 7.5, 150 mM NaCl, 0.5%
NaCl, 50 mM NaF), and lysates were pooled (300 mg total). Clarified lysates
were immunoprecipitated with affinity-purified anti-CUL4A antibody (2 g/mg
lysate with or without 10 g/mg antigen peptide). Immunocomplexes were re-
solved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and stained with Coomassie blue, and the protein bands were digested
with trypsin and subjected to mass spectrometric analysis at the University of
North Carolina Proteomics Core Facility. To purify the endogenous VprBP
complex, an analogous protocol was used but with U2OS cells.
Plasmids, cell culture, and cell transfection. Plasmids expressing human
CUL4A and DDB1 were as previously described (14, 18). pFSZ2-VprBP-FLAG
was the kind gift of L. J. Zhao (St. Louis University) and was used to subclone
VprBP into a pcDNA3-based mammalian expression vector. Mutations were
introduced by site-directed mutagenesis using a QuikChange kit (Stratagene)
and verified by DNA sequencing. Cell lines were cultured as follows: HeLa cells
were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal
bovine serum (FBS) in a 37°C incubator with 5% CO2; U2OS cells were cultured
in McCoy’s 5A medium containing 15% FBS; HCT116 cells were cultured in
McCoy’s 5A medium containing 10% FBS; WI-38 and WI-38/E6 cells were
cultured in minimal essential medium with sodium pyruvate, nonessential amino
acids, and 10% FBS; and 293T cells were cultured in Dulbecco’s modified Eagle’s
medium containing 10% newborn calf serum. Cell transfections were carried out
using a calcium-phosphate buffer.
Gel filtration chromatography. To examine the elution profile of CUL4A and
associated proteins, HeLa cells were lysed with the 0.5% NP-40 lysis buffer, and
clarified lysate was resolved through a Superdex 200 gel filtration column (GE/
Amersham). Fractions (0.5 ml) were collected, and 50 l of each was resolved via
SDS-PAGE and immunoblotted with antibodies as indicated on the figures.
High-molecular-weight standards (GE/Amersham) were resolved through the
same column, and the peak fraction for each was determined.
RNA interference. Recombinant Dicer-generated small interfering RNA
(siRNA) to VprBP was generated by first amplifying bp 4008 to 4625 of VprBP
cDNA using PCR primers with 5 overhangs with T7 promoter sequences. This
PCR product was then used as a template for in vitro transcription of both
strands of a double-stranded RNA (dsRNA) by using a T7 RiboProbe kit (Pro-
mega) and then annealing the dsRNA by heating the transcribed mixture to 95°C
and slowly cooling it to room temperature. This dsRNA was then immediately
added, without purification, to a reaction mixture containing 8 U of recombinant
Dicer (Stratagene) and Dicer reaction buffer to a total of 500 ml. After being
digested for 18 h at 37°C, the Dicer products were purified by a series of three
spin columns (G-25 [Amersham, Piscataway, NJ], EZ-pure [Millipore, Bedford,
MA], and Microcon-100 [Millipore]) (27). The final product was resolved on a
15% native polyacrylamide gel along with a known quantity of a synthetic siRNA
to estimate the final concentration. Control green fluorescent protein-recombi-
nant Dicer siRNAs were prepared as described previously (27).
Two duplex oligonucleotides encoding human VprBP-specific short hairpin
RNA (shRNA) (sh1, 5-CCGGGAATACTCTTCAAGAATGATGCCTCCTG
TCACATCATTCTTGAAGAGTATTCTTTTTG-3; sh2, 5-CCGGGAAATA
CCTCGTCCTTCTATGCTTCCTGTCACATAGAAGGACGAGGTATTTCT
TTTTG), one duplex encoding human DDB1-specific shRNA (5-CCGGCAG
CATTGACTTACCAGGCATCCTCCTGTCAATGCCTGGTAAGTCAATGC
TGTTTTTG-3), and one duplex oligonucleotide encoding firefly luciferase-spe
cific shRNA (5-CCGGGAGCTGTTTCTGAGGAGCCCCTCCTGTCAGGCT
CCTCAGAAACAGCTCCCGGTTTTTG-3) were ligated into the pMKO.1
vector (Addgene plasmid 8452). Retrovirus production and transduction were
carried out according to a standard protocol. Twenty-four hours after infection,
noninfected cells were removed by the addition of puromycin (2 g/ml) for 2
days before analysis for cell cycle, cell proliferation, protein expression, and
complex formation. The siRNA sequence targeting DDB1 used in the experi-
ment shown in Fig. 5C was previously described (35) and was transfected to
HCT116 cells using Dharmafect (Dharmacon).
Flow cytometry. To analyze DNA content by propidium iodide (PI) staining,
cells were fixed in 75% ethanol overnight at 4°C, washed once in 1 phosphate-
buffered saline (PBS) plus 1% FBS, and then permeabilized for 30 to 45 min at
37°C in 1 PBS, 0.1 mg/ml RNase A, and 0.1% Triton X-100. The fixed and
permeable cells were stained with 50 g/ml PI for at least 90 min at room
temperature, shielded from light. To analyze ongoing replication of DNA by
bromodeoxyuridine (BrdU) labeling, cells were fixed in 80% ethanol overnight at
4°C and then washed once in 1 PBS. Nuclei were isolated by incubating cells in
0.1 M HCl–0.08% pepsin for 20 min at 37°C, and then DNA was denatured by
incubating cells in 2 M HCl for a further 20 min at 37°C. After the HCl was
neutralized with 2 volumes of 0.1 M sodium borate, pH 8.5, the cells were washed
once with immunofluorescence assay (IFA) buffer (10 mM HEPES [pH 7.3], 150
mM NaCl, 4% FBS, 0.1% sodium azide) plus 0.5% Tween 20. The cells were
labeled with fluorescein isothiocyanate (FITC)-conjugated anti-BrdU (BD Bio-
sciences) at 1:10 in IFA buffer plus Tween for 45 min at room temperature and
then washed once with IFA buffer plus Tween. Finally, cells were stained for
DNA content by incubation for 30 min at room temperature with IFA buffer–0.1
mg/ml RNase A–50 mg/ml PI. Stained cells were analyzed at the University of
North Carolina School of Medicine Flow Cytometry Facility on either a FAC-
Scan (Becton Dickinson) or CyAN (Dako Cytomation) flow cytometer, and data
were analyzed using Summit software, version 4.3 (Dako Cytomation).
Molecular combing. To analyze the properties of replication forks, HeLa cells
were double labeled by incubation, first in medium with 100 M iododeoxyuri-
dine (IdU) for 10 min and second in 50 M chlorodeoxyuridine (CldU) for 20
min. DNA spreads were generated and stained for IdU and CldU, and individual
replication tracks were analyzed as described previously (41).
Chromatin fractionations. Cells were lysed in CSK buffer (10 mM PIPES-
KOH [pH 6.8], 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 0.5 mM phenyl-
methylsulfonyl fluoride, 1 mM glycerophosphate, 50 mM NaF, 1 mM Na3VO4,
and protease inhibitor cocktail tablet) containing 0.5% Triton X-100 as described
in Cook et al. (7). Portions were reserved (whole-cell extracts) prior to fraction-
ation by low-speed centrifugation. Detergent-insoluble pellets were treated for 5
min with 15 U of micrococcal nuclease (Roche) in CSK buffer supplemented with
2 mM CaCl2 and then separated again by centrifugation. Proteins in the nucle-
ase-soluble fractions of these digests were defined as chromatin bound. Densi-
tometry analysis was performed using the public domain NIH Image program
(U.S. National Institutes of Health [http://rsb.info.nih.gov/nih-image/]).
Generation of VprBP mutant mice and mouse embryonic fibroblasts (MEFs).
A 9.3-kb fragment of mouse genomic DNA, spanning from exon 5 to intron 8 of
the VprBP gene, was amplified by PCR from mouse 129 SvEv embryonic stem
(ES) cell genomic DNA and verified by DNA sequencing. LoxP sites were
inserted at the 5 and 3 ends of a 2,358-bp genomic fragment containing exons
7 and 8 encoding 203 amino acid residues (Val172 to Ala374). To select for
homologous recombination, a neomycin resistant gene (Neor), flanked by Flp
recognition target sites, was inserted immediately upstream of the 5 LoxP
deletion site, and a thymidine kinase negative selection marker was inserted
upstream of exon 5. Following homologous recombination into ES cells, Cre or
Flp recombinase expression vectors were transiently transfected to delete either
the targeted exons (exon 7 and 8) or the Neor cassette. The recombination event
was confirmed by Southern blot analysis with probes against either exons 5 and
6 (probe 2) or exons 7 and 8 (probe 1). Three independent clones were injected
into C57BL/6 blastocysts, and the resulting chimeras were mated with C57BL/6
females to generate VprBPflox/ or VprBPfrt/ heterozygous mice. Transmis-
sion of the targeted loci was confirmed by Southern blotting and PCR. Hetero-
zygous offspring were intercrossed to produce homozygous mutant animals.
Primers for genotyping the conventional knockout mice were the following:
FW-5-TGAGTGGTTGGATCCGTACTAC-3, RV-5-TTAAGGCCTGTCGA
CAAGCG-3, and RV-5-CCCAAACTAGAAGGTGTGCA-3. Primers for geno-
typing the conditional mice were FW-5-GCATACATTATACGAAGTTATGG
ATCC-3 and RV-5-GTATGCTATACGAAGTTATGCTAGCCT-3.
To generate the VprBP null MEFs, we mated heterozygous VprBPflox/ and
VprBPfrt/ mice. Embryos were isolated at day 13.5 post coitus (E13.5). MEFs
at early passages were infected with empty vector (pMX) or pMX-Cre recom-
binase expressing retrovirus (kindly provided by Keiichi Nakayama). Two days
after infection MEFs were selected with 2 g/ml of puromycin for 2, 4, or 10 days
before cell cycle analysis.
RESULTS
VprBP associates with DDB1-CUL4 E3 ligase complex. We
previously used large-scale immunoprecipitation and mass
spectrometry to identify a series of CUL4A/DDB1-interacting
proteins and used this approach to define a common motif
found in potential CUL4A/DDB1 substrate receptors, the
DWD box (14). The most abundant of these DWD proteins in
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our CUL4A immunocomplex was VprBP(Fig. 1A, left panel).
To characterize VprBP, we generated a rabbit polyclonal an-
tibody to VprBP, performed a large-scale immunoprecipita-
tion in U2OS cells (Fig. 1A, right panel), and submitted bands
that were specifically competed off by antigen peptide for mass
spectrometric identification. We found, as determined by Coo-
massie blue staining, that VprBP associated with almost stoi-
chiometric amounts of DDB1, smaller amounts of CUL4A, the
FIG. 1. VprBP specifically associates with DDB1-CUL4 E3 ligase. (A) CUL4A and VprBP complexes were immunopurified from human BT474 cells
and U2OS cells, respectively, and resolved by SDS-PAGE, followed by staining with Coomassie brilliant blue. Bands identified by mass spectrometry are
indicated. Subunits of the COP9/signalosome (CSN) are indicated. (B) Endogenous VprBP and CUL4A coimmunoprecipitate. U2OS cells were treated
with MG132 (25 M for 5 h) and then lysed with 0.5% NP-40 lysis buffer and immunoprecipitated with antibodies against VprBP or CUL4A.
Immunocomplexes were resolved by SDS-PAGE and immunoblotted with the indicated antibodies. Proteins identified by mass spectrometry are
indicated with arrows. (C) VprBP associates with CUL4A but not other cullins. 293T cells were transfected with pcDNA3-myc3-cullin plasmids, and
lysates were immunoprecipitated and immunoblotted as indicated. (D) VprBP exists in very-high-molecular-weight complexes. An NP-40 lysate derived
from HeLa S3 cells was resolved on a Superdex 200 gel filtration column, along with molecular weight standards as indicated. The void volume
corresponded to a molecular mass over 700 kDa, and the input control was 100 g of HeLa S3 lysate. Equal volumes of each fraction were resolved by
SDS-PAGE and immunoblotted as indicated. IP, immunoprecipitation; IB, immunoblotting; , anti; Ag, antigen; MW, molecular weight (in thousands).
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subunits of the COP9/signalosome deneddylase, and DDA1
(for DDB1-associated 1; also called DET1) (30). In order to
verify the specificity of these interactions, we performed im-
munoprecipitation and immunoblotting experiments (Fig. 1B).
VprBP coimmunoprecipitated preferentially with NEDD8-
modified CUL4A, which was more noticeable upon enrich-
ment of CUL4A-NEDD8 by proteasome inhibition. Since both
binding with COP9/signalsome subunits and neddylation of
CUL4 are associated with active cullin ligases, it is likely that
VprBP is associated with the active form of DDB1-CUL4-
ROC1.
To determine if VprBP specifically binds CUL4-DDB1 or if
it binds all cullin family members, we immunoprecipitated
ectopically expressed individual cullins and performed immu-
noblotting assays for endogenous VprBP (Fig. 1C). VprBP was
detected only in the CUL4A immunocomplex and not in any of
four other cullins we examined, suggesting that VprBP func-
tions specifically through CUL4.
The Coomassie blue-stained immunocomplex suggested that
VprBP might interact with multiple cellular proteins. To test
this idea specifically, we separated a lysate of HeLa cells by gel
filtration chromatography (Fig. 1D). VprBP exists in com-
plexes of more than 450 kDa to greater than 700 kDa in size,
and we were unable to detect by Western blotting any VprBP
in size fractions corresponding to a monomeric form. This
finding, combined with the presence of abundant DDB1 in the
VprBP immunocomplex, implies that VprBP primarily func-
tions through its interactions with the CUL4A ubiquitin ligase
as opposed to acting as a monomer. All of the fractions that
contained VprBP also contained abundant DDB1 and CUL4.
These results suggest that DDB1 is a major functional partner
of VprBP in vivo and that VprBP, through DDB1, associates
with CUL4-based E3 ligase complexes.
The WD40 domain of VprBP and the N-terminal domain of
CUL4A are both required and sufficient for binding of VprBP
with DDB1-CUL4A. We have previously shown that the N
terminus of CUL4A interacts with DDB1 and that DDB1
functions as a linker to recruit DWD proteins (14, 18). To
verify that VprBP is likewise recruited to the CUL4 complex,
we coexpressed VprBP with a panel of CUL4A mutants (Fig.
2A) and found that deletion of the N-terminal 52 or 100 amino
acids, which constitute the DDB1-interaction domain, com-
pletely abrogated the VprBP-CUL4A interaction (Fig. 2B),
providing further support that DDB1 bridges VprBP to
CUL4A. In addition to its C-terminal WD40 domain, VprBP
contains conserved domains in its N terminus. We examined
whether these domains might influence its binding to CUL4A/
DDB1. Expression of the C terminus of VprBP alone, contain-
ing the WD repeats and a highly acidic “tail,” was sufficient to
bind endogenous CUL4A and DDB1, indeed, even more
abundantly than full-length VprBP (Fig. 2C). This observation,
combined with the inability of the conserved N-terminal do-
main (N-terminal 751 residues of VprBP) to interact with
CUL4A or DDB1, indicates that VprBP interacts with DDB1-
CUL4 through its WD40 domain.
VprBP expression is essential for normal proliferation and
DNA replication. To explore the cellular function of VprBP
through the use of RNA interference, we first used recombi-
nant Dicer to generate siRNA to VprBP (Fig. 3A). Efficient
VprBP silencing was achieved, resulting in a more than 90%
reduction of VprBP protein in transfected U2OS cells (Fig.
3A) and an obvious proliferation defect. To quantify that phe-
notype, we transfected U2OS cells with siRNA silencing
VprBP as well as DDB1 and plated equal numbers of cells 72 h
after transfection to measure cellular proliferation. We found
that silencing VprBP as well as DDB1 strongly inhibited U2OS
cell proliferation (Fig. 3B).
To confirm this result with different siRNA sequences and in
different cell lines, we produced three hairpin RNA sequences
targeting different regions of VprBP and identified two that
were very successful at silencing (Fig. 3C) and at reproducing
the siRNA growth arrest phenotype (Fig. 3D). Transduction of
a retrovirus expressing one of the two shRNA constructs in-
duced nearly complete silencing (Fig. 3E) and a pronounced
S-phase accumulation compared with control luciferase
shRNA-infected HeLa cells (Fig. 3F). Treatment of VprBP-
silenced cells with the S-phase inhibitor hydroxyurea, thymi-
dine, or aphidicolin (not shown) did not result in further ac-
cumulation of S-phase cells (27.9% in untreated cells versus
27.6% in hydroxyurea-treated or 23.8% thymidine-treated
cells), whereas the same treatment with luciferase siRNA in-
creased S-phase cells from 12.7% to 35.5% in hydroxyurea-
treated and 40.3% in thymidine-treated cells (Fig. 3F). Treat-
ment of VprBP-silenced cells with the metaphase inhibitor
nocodazole caused a substantially reduced G2/M accumulation
(from 17% to 25.9%) compared with control luciferase-si-
lenced cells (from 12.7% to 59.9%). Together, these results
indicate that silencing of VprBP caused almost complete ces-
sation of DNA synthesis in HeLa cells.
The function of VprBP is required for progression through
S phase. To further characterize the S-phase phenotype of cells
lacking VprBP, we pulse-labeled HeLa cells with BrdU for 30
min and examined the pattern of its incorporation (Fig. 4A).
The percentage of BrdU-positive cells was increased in
VprBP-silenced (35%) cells compared with control cells trans-
fected with shRNA targeting luciferase (26%). The rate of
BrdU incorporation, however, was markedly reduced in
VprBP-silenced cells, with the mean BrdU intensity in VprBP-
silenced cells (50 arbitrary units) reduced to slightly less than
half that of control cells (96 arbitrary units). To determine
whether silencing VprBP had the same or different effects on
BrdU incorporation throughout S phase, we gated S-phase
cells into six different periods (R1 to R6) and calculated the
mean BrdU intensity of each period. Silencing VprBP had very
little effect, if any, on the rate of BrdU incorporation in cells in
immediate-early S phase, reducing mean BrdU intensity only
slightly from 46 in control cells to 44 in VprBP-silenced cells
(Fig. 4B, R1 population). Silencing VprBP, however, progres-
sively reduced the mean BrdU intensity in cells progressing
through S phase, with cells at middle and later S phase showing
the most profound reduction of BrdU incorporation (Fig. 4B).
The mean BrdU intensity was reduced from 69 in control cells
to 50 in VprBP-silenced cells during early S phase (R2 popu-
lation), from 93 to 57 and from 126 to 63 for two middle
S-phase populations (populations R3 and R4, respectively),
from 139 to 60 for a middle-to-late S-phase population (R5),
and from 112 to 60 in a late-S-phase population (R6). These
results are consistent with a model where VprBP performs a
critical function for S-phase progression but not for S-phase
entry.
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VprBP silencing decreases active replication forks and in-
creases new origin firing. We considered several possibilities to
explain the defect in S-phase progression, including defects in
replication origin licensing, the ability to activate origins, rep-
lication fork elongation, and replication fork stability. To eval-
uate origin firing and fork elongation, we conducted DNA
fiber analysis to examine the replication of DNA at individ-
ual replication forks. HeLa cells were transduced with ret-
rovirus expressing shRNA targeting either control luciferase
or VprBP. At 72 or 90 h after viral transduction, cells were
first labeled for 10 min with IdU and then washed and
labeled for 20 min with CldU. After the second pulse, cells
were harvested; a portion was lysed on a glass slide, the slide
was tilted, and the DNA fibers were gently straightened and
aligned (combed). The DNA fibers were then fixed, and the
presence of IdU or CldU was detected by immunostaining
with red (AlexaFluor 594) and green (AlexaFluor 488) flu-
orescent antibodies, respectively. The DNA fiber-labeling
technique allowed us to distinguish between replication
forks that were active during both the first and second pulses
(ongoing forks), forks that initiated only during the second
pulse (newly fired origins), and forks that were active only
during the IdU pulse (terminations) (Fig. 4C, left panel).
The relative proportions of tracks with different label com-
FIG. 2. The WD domain of VprBP is sufficient to interact with CUL4A/DDB1. (A) Schematic diagrams of CUL4A and VprBP mutants used
in panels B and C. (B) VprBP interacts with the substrate-recruiting N terminus of CUL4A. 293T cells were transfected with pFSZ2-VprBP-FLAG
and pcDNA3-myc3-CUL4A plasmids as indicated. NP-40 (0.5%) lysates were immunoprecipitated with anti-FLAG (M2), resolved by SDS-PAGE,
and immunoblotted as shown. The CUL4A mutants used are diagrammed in panel A. (C) The WD domain of VprBP is sufficient to interact with
CUL4A/DDB1. 293T cells were transfected with pcDNA3-myc3-VprBP, wild-type, or mutants as indicated. VprBP-DDB1/CUL4 interactions were
determined by immunoprecipitation-Western blotting with the indicated antibodies. WT, wild type; IP, immunoprecipitation; n.s., nonspecific; ,
anti; N751, conserved N-terminal domain of VprBP; WD40, residues 994 to 1507 of VprBp; N52 and N100, deletion of the N-terminal 52 and
100 residues of CUL4A, respectively; 24, deletion of residues 439 to 462; ROC, deletion of residues 594 to 612; Nd8, K705R mutated Nedd8
conjugation site.
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FIG. 3. VprBP is required for normal cellular proliferation and S-phase progression. (A) Recombinant Dicer-generated VprBP siRNA is
efficient in silencing. U2OS cells were transfected with recombinant Dicer-generated VprBP siRNA or green fluorescent protein siRNA or
synthetic DDB1 siRNA; 72 h after transfection, cells were lysed, and lysates were resolved by SDS-PAGE and immunoblotted as indicated.
(B) Silencing VprBP and DDB1 inhibits cellular proliferation. At 72 h after transfection as described in panel A, equal numbers of siRNA-
transfected U2OS cells were plated. The numbers of cells were counted after 72 more hours of culturing and divided by the numbers of cells initially
plated, with a standard error of more than four separate counts indicated. (C) Two VprBP shRNA constructs efficiently silence expression.
WI-38/E6 cells were infected with retroviruses expressing empty pMKO.1 vector (C) or vectors expressing two different shRNA sequences to
VprBP (sh1 and sh2). At 24 h after infection, the cells were selected with 2 mg/ml puromycin for 48 h, and then viable cells were lysed in 0.5%
NP-40 lysis buffer. Lysates were resolved by SDS-PAGE and immunoblotted as indicated. (D) Both VprBP shRNAs contribute to an inhibition
of cellular proliferation. At 72 h after infection with shRNA against VprBP or empty viral vector (48 h after selection), equal numbers of viable
WI-38 or WI-38/E6 cells were replated. At 72 h after plating, cell numbers were counted and normalized against empty vector control cells (control
cell growth equals 100% on the graph). A standard error of more than four counts is indicated. (E) shRNA retroviruses to VprBP efficiently silence
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binations can be used to evaluate changes in the frequency
of origin firing or replication fork progression due to an
environmental stress (6, 26). As can be seen in Fig. 4C, the
percentage of tracks with only the first pulse (IdU-only
tracks) from two time points was similar between control
cells infected with shRNA virus targeting luciferase (10%)
and cells infected with shRNA virus targeting VprBP(9%),
indicating that the relative number of forks that terminated
during the IdU (first) pulse was unchanged by the silencing
of VprBP.
However, we did find a striking change in the firing of new
origins. In VprBP-silenced HeLa cells, the proportion of newly
fired DNA replication forks increased significantly, i.e., from
12% and 5% in control cells infected with shRNA virus tar-
geting luciferase to 22% and 14% in VprBP-silenced cells at 72
and 90 h after shRNA viral infection, respectively (Fig. 4C). To
VprBP expression in HeLa cells. HeLa cells were infected with pMKO.1 retroviruses encoding shRNA targeting VprBP or luciferase. At 24 h after
infection, cells were selected for 48 h with 2 g/ml puromycin. Dead cells were washed away with PBS, and selected cells were trypsinized, lysed,
and analyzed for protein expression. (F) VprBP-silenced HeLa cells are arrested in S phase. Trypsinized cells from panel C were replated into new
dishes. After 24 h (96 h postinfection of shRNA virus), cells were treated with hydroxyurea (1 mM), thymidine (2 mM), or nocodazole (0.1 g/ml)
as indicated. At 24 h posttreatment, cells were trypsinized and fixed overnight in 75% ethanol. After PI staining, the cell cycle was analyzed by flow
cytometry. The x axes indicate PI staining intensity (DNA content); the y axes indicate cell counts. GFP, green fluorescent protein; luc, luciferase.
FIG. 4. VprBP silencing increases the firing of new replication forks and impairs DNA replication. (A) HeLa cells were infected with pMKO.1
retroviruses encoding shRNA to VprBP or luciferase. At 80 h postinfection, cells were selected for 56 h with puromycin (2 g/ml) to remove
uninfectecd cells and were pulse-labeled with 10 M BrdU for 30 min. After labeling, the cells were washed with 1 PBS, trypsinized, and fixed
in 80% ethanol–20% 1 PBS overnight. After cells were stained with an FITC-conjugated anti-BrdU antibody and PI, they were analyzed by flow
cytometry as shown. Mean BrdU staining intensity was calculated after gating for BrdU-positive cells and graphed  standard deviation. (B) VprBP
silencing obstructs elongation of DNA replication. S-phase cells from panel A were gated into six different populations based on their DNA
content, and mean BrdU intensity was calculated. (C) VprBP silencing increases newly fired origins of replication. At 72 or 90 h postinfection with
shRNA retroviruses targeting either control luciferase or VprBP, HeLa cells were first labeled for 10 min with IdU, washed, and then labeled for
20 min with CldU. The cells were then trypsinized and resuspended in 1 PBS. After fixation, DNA was combed out onto the slides and stained
for IdU (red) and CldU (green); individual replication tracks were counted and analyzed. After the combing step, the numbers of IdU-only,
CldU-only, and IdU-CIdU tracks were quantified. (D) VprBP shRNA inconsistently affects the rate of DNA elongation. The length of green (CldU
stained) sections of actively elongating (red-green) tracks were measured in HeLa cells as described in panel C, and data from control cells
transduced with shRNA targeting luciferase were plotted as 100%. Luc, luciferase.
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determine whether silencing VprBP influences overall replica-
tion fork displacement rates, we measured the CldU portion of
IdU-CldU (conjoined red and green) tracks in cells infected
with shRNA virus targeting luciferase and VprBP. When the
CldU portion of the IdU-CldU tracks was compared among
the various infected cells, we could not detect any significant
change in length (Fig. 4D). Therefore, we concluded that the
low BrdU incorporation seen in Fig. 4B cannot be explained by
the slowing down of the replication fork. One plausible expla-
nation for the increase in the relative number of newly fired
origins, combined with a decrease in BrdU incorporation, is
that silencing VprBP either destabilizes replication forks or
impedes the elongation of some, but not all, forks, resulting in
replication stress that subsequently stimulates the firing of
dormant origins (see Discussion).
VprBP associates with chromatin in a DDB1-independent
and cell cycle-dependent manner. To further probe the func-
tion of VprBP in DNA replication, we determined the expres-
sion of VprBP during the cell cycle and investigated whether
VprBP might directly associate with chromatin in a cell cycle-
specific manner. To test this notion, we synchronized HeLa
cells by arresting them at the G1-S boundary by a double-
thymidine block and then releasing them and taking samples
throughout the cell cycle. We prepared either total cell lysates
or fractionated lysates of these cells to enrich for chromatin-
associated proteins. As the results show, the steady-state levels
of VprBP remain relatively constant during interphase but
decrease in nocodazole-treated cells (Fig. 5A). VprBP binds to
chromatin, and the chromatin-bound fraction oscillates during
the cell cycle; VprBP is not detected on chromatin in cells at
the G1-S boundary, and it increases from early S through G2,
decreases upon return to G1 phase, and is not detectable on
chromatin after arrest of cells in prometaphase by nocodazole
treatment (Fig. 5B). This behavior is in contrast to MCM2,
which is loaded onto chromatin to license origins in G1 and
then leaves chromatin during S phase as DNA is replicated and
FIG. 5. VprBP and CUL4A associate with chromatin during S and G2 phases of the cell cycle. (A) HeLa cells were synchronized at the G1-S
boundary by double-thymidine block and then released into fresh medium. Time points were collected as indicated, with a fraction of cells being
fixed for flow cytometry analysis, and the rest were pelleted and frozen at 80°C. The frozen pellets were then chromatin fractionated (see
Materials and Methods), and whole-cell extract and chromatin-associated proteins were resolved by SDS-PAGE and immunoblotted as indicated.
(B) VprBP is not required for CUL4A, DDB1, or MCM2 loading onto chromatin. HeLa cells were transduced with VprBP shRNA and then
selected with puromycin for 24 h starting 24 h after transduction. The cells were then passaged, and 36 h later they were trypsinized and pelleted.
Pellets were fractionated as described in panel A, resolved by SDS-PAGE, and immunoblotted as indicated. Loading controls were histone H3 in
the chromatin fraction and alpha-tubulin in the whole-cell extract. (C) DDB1 is not required for VprBP association with chromatin. HCT116 cells
were transfected with siRNA to DDB1 or scrambled control siRNA. At 72 h posttransfection cells were collected, and chromatin fractions were
prepared. When the whole-cell extract is normalized to tubulin, siRNA to the DDB1 lane resulted in 28% of the VprBP compared to the control
lane. When the chromatin fraction is normalized to ORC2, siRNA to VprBP showed 42% of the VprBP, compared to the control lane, bound to
chromatin.
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is not detectable on chromatin in mitotic cells (40). CUL4A
also binds to chromatin but exhibits a different pattern from
both VprBP and MCM2: it is clearly detectable on chromatin
in cells at the G1-S boundary and remains relatively unchanged
from early S to G2. These results suggest that VprBP is re-
cruited to chromatin as DNA is being replicated and is re-
leased from chromatin before mitosis. This interpretation is
consistent with previous findings that silencing VprBP did not
appreciably reduce the BrdU incorporation in cells at imme-
diate-early S phase but caused a pronounced reduction in
BrdU incorporation in cells at middle to late S phase. More-
over, silencing VprBP did not affect MCM2 chromatin loading,
supporting the interpretation that VprBP functions in DNA
replication at a time after formation of the prereplication
complex.
The findings that VprBP strongly associates with DDB1 and
binds to chromatin prompted us to explore whether VprBP
may perform a function in DNA repair. We again isolated
chromatin from control cells or VprBP-depleted cells that
were either untreated, UV irradiated, or MG132 treated and
examined chromatin association of various proteins. Consis-
tent with a previous report (13), both DDB1 and the unned-
dylated form of CUL4A were associated with chromatin (Fig.
5B). No chromatin association was detected for DDB1,
CUL4A, or VprBP in nocodazole-treated cells while the
steady-state levels of DDB1 and CUL4A were not affected by
nocodazole treatment, confirming their cell cycle-dependent
association. UV treatment increased the association of DDB1
and also CUL4A with chromatin, supporting their roles in
mediating the DNA damage response. In contrast to the re-
sults for DDB1 and CUL4A, UV treatment did not apprecia-
bly change either VprBP’s association with chromatin or its
steady-state level, suggesting that VprBP is unlikely to play a
major role in a DDB1-mediated DNA damage response.
Silencing VprBP did not detectably affect CUL4A or DDB1
association with chromatin during either normal cell prolifer-
ation or after UV treatment (Fig. 5B), arguing against the
model that VprBP recruits DDB1 and CUL4A to chromatin in
either normal or DNA-damaged cells. Conversely, silencing
DDB1 did not detectably affect VprBP binding to chromatin
either (Fig. 5C). To verify this finding, we normalized the
steady-state level of VprBP protein in the whole-cell extract to
that of -tubulin and the level of VprBP protein in the chro-
matin fraction to that of the Orc2 protein. Compared to con-
trol cells transfected with scrambled siRNA oligonucleotides,
the whole-cell extract of DDB1-silenced cells contained 28%
of the control amount of VprBP, whereas the chromatin frac-
tion of DDB1-silenced cells contained 42% of control VprBP.
These results suggest that chromatin binding of DDB1-CUL4
and VprBP appears to occur independently for each protein.
The steady-state level of VprBP was reduced in DDB1-si-
lenced cells as noted previously (Fig. 3A), suggesting that bind-
ing with DDB1 may stabilize VprBP.
VprBP is essential for embryonic development. To deter-
mine the in vivo function of VprBP, we disrupted the VprBP
gene in murine ES cells by gene targeting (Fig. 6A and B). Two
different targeting vectors were generated, one for conditional
and one for conventional deletion of a 2,358-bp genomic frag-
ment containing exons 7 and 8 encoding 203 amino acid resi-
dues (Val172 to Ala374) of mouse VprBP (see Materials and
FIG. 6. VprBP disruption results in early embryonic lethality. (A) Disruption of the VprBP gene. Schematic diagram of targeting vectors and
targeted alleles. (B) Southern blot analysis of genomic DNA from targeted ES clones. (Genomic DNA was digested with HindIII and probed with
the internal probe (probe 2; left panel). VprBP ES clones displayed a 17.5-kb wild-type band and a 6.7-kb band corresponding to the knockout
allele. Screening of conditional mutant clones was performed using probe 2 (right panel). The wild-type allele, the nontargeted original mutant
band, and the floxed allele are indicated. (C) Embryos from VprBP/ heterozygous intercrosses were collected on the indicated embryonic days,
and the genotypes were determined by Southern blot analysis or PCR. DNA extracted from tails of 21-day-old pups was also subjected to the same
procedure. ED, empty deciduae; na, not available. (D) Morphological analysis of E7.5 and E9.5 embryos isolated from VprBP/ intercrosses. A
typical photograph is shown for normal and mutant at E7.5 and E8.5 embryos freshly dissected from decidua. TK, thymidine kinase; WT, wild type;
mt, mutant; Con, conditional.
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Methods). To date, no VprBP null mice have been recovered,
whereas VprBP/ and wild-type littermates were both pro-
duced at a Mendelian ratio, appeared normal, and were fertile
(Fig. 6C). These data indicate that VprBP is essential for
mouse embryonic development. To determine the time at
which the VprBP mutation becomes lethal, we examined em-
bryos from VprBP/ intercrosses at various developmental
stages. All VprBP/ embryos between E10.5 and E13.5 were
completely resorbed. Systematic analysis of embryos from day
E7.5 to E9.5 generated from mating heterozygotes failed to
detect VprBP null embryos (Fig. 6C). Empty decidua and re-
mains of resorbed embryos were often observed at E8.5 or
E7.5 in heterozygous intercrosses but were rarely seen in back-
crosses between heterozygous and wild-type mice (Fig. 6D and
data not shown). These results indicate that the lethality of
VprBP null embryos may occur before E7.5.
Deletion of VprBP in MEFs resulted in decreased DNA rep-
lication and increased apoptosis. We also generated a condi-
tional allele and obtained VprBPflox/ embryos at the predicted
Mendelian frequencies (data not shown), confirming that the
insertion of the floxP site into the VprBP locus did not cause
any significant adverse effect on the function of VprBP and the
development of animals. This conditional allele allowed us to
derive littermate VprBPflox/ MEFs for genetically determining
the function of VprBP. Infection of VprBPflox/ MEFs with a
pMX-Cre retrovirus expressing the Cre recombinase resulted
in nearly undetectable VprBP protein expression 24 h after
infection (Fig. 7A), confirming a successful deletion of both
VprBP alleles. At 24 and 96 h after pMX-Cre retroviral infec-
tion, we pulse-labeled wild-type and VprBPflox/ MEFs with
BrdU for 1 h and examined cell cycle progression by fluores-
cence-activated cell sorting analysis. Twenty-four hours after
pMX-Cre viral transduction, the BrdU-positive cell population
was decreased by nearly 60%, from 7.2% in pMX-infected
VprBPflox/ MEFs to 3.0% in pMX-Cre-infected VprBPflox/
MEFs. A substantial decrease in the S-phase cell population
was also observed at a later time point, i.e., from 9.4% to 2.9%
96 h after pMX-Cre transduction (Fig. 7B). Accompanying the
decrease in S-phase cell number by the deletion of VprBP was
a small increase in the G1 cell population from 58.1% to 60.8%
and from 46.3% to 52% at 24 and 96 h after viral transduction,
respectively. VprBP loss did not significantly affect the G2 pop-
ulation. The major consequence resulting from impaired DNA
replication after VprBP deletion is a substantial increase in
apoptosis, from 10% in pMX-infected VprBPflox/ MEFs to
22.3% in pMX-Cre-infected MEFs (Fig. 7C).
DISCUSSION
In this study, we examined the cellular function of the novel
DDB1-CUL4A-interacting protein VprBP, which has recently
been shown to be a major target for the function of the HIV-1
FIG. 7. VprBP deletion in MEFs results in reduced BrdU incorporation and increased apoptosis. (A) Wild-type (WT) and VprBPflox/ MEFs
were transduced with either control pMX or pMX-Cre retroviruses. Cells were collected 24 or 96 h after puromycin selection, and VprBP deletion
was verified by Western blotting. (B) pMX- or pMX-Cre-transduced MEFs as described in panel A were pulse-labeled with BrdU for 30 min and
then fixed and stained with FITC-conjugated anti-BrdU antibody and PI. BrdU intensity and DNA content (PI intensity) were measured by flow
cytometry and quantified using Summit software, version 4.3. (C) pMX- or pMX-Cre-transduced MEFs as described in panel A were selected with
puromycin for 24 h and then stained with annexin V. Apoptotic cells were determined by flow cytometry.
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Vpr protein. We demonstrated that VprBP interacts specifi-
cally with CUL4 but not other cullins and associates with the
DDB1-CUL4A E3 ligase in a manner analogous to other
DWD proteins, binding through DDB1 with the N terminus of
CUL4A and requiring only its WD40 domain (Fig. 1 and 2).
VprBP preferentially interacts with the NEDD8-modified
form of CUL4A and forms a complex with the COP9/signalo-
some, both indicative of an active CUL4-ROC1 ligase. To-
gether, these results suggest that VprBP functions by either
recruiting specific substrates or promoting the recruitment of
other substrates to the DDB1-CUL4-ROC1 E3 ligase.
Our biochemical and genetic analyses support the notion
that the major functions of VprBP are mediated by DDB1.
First, very little monomeric VprBP is present in the cell, and all
detectable VprBP is present in fractions that are larger than
500 kDa and also contain both DDB1 and CUL4A. Second, in
U2OS cells where we examined the VprBP immunocomplex by
Coomassie blue staining, VprBP associates with DDB1 nearly
stoichiometrically (Fig. 1). Third, genetically, deletion of the
Ddb1 gene, like that of VprBP, also caused early embryonic
lethality, inhibition of cell proliferation, and significant apop-
tosis (4, 5). Although not distinct, these phenotypes are con-
sistent with the expectation that DDB1 is essential for the
function of VprBP. A direct genetic test of the functional
dependency of VprBP on DDB1 is hindered by the early em-
bryonic lethality of both Ddb1 and VprBP deletions and is
further complicated by the broad function of DDB1 because of
its binding with as many as 90 DWD proteins.
VprBP is required for normal progression of DNA replica-
tion. The major findings of this study are that VprBP’s function
is essential for cells to progress through S phase and, thus, cell
proliferation and embryonic development. Silencing VprBP in
U2OS or WI-38 cell lines (data not shown) or deletion of the
VprBP gene in MEFs resulted in a substantial decrease of
BrdU incorporation and subsequent inhibition of cell prolifer-
ation. Silencing VprBP had no significant effect on either the
binding of MCM2 to chromatin or on the BrdU incorporation
in immediate-early S-phase cells, arguing against an essential
function of VprBP in the assembly of the prereplication com-
plex or in the initiation of DNA replication. Our combing
experiments also indicate that termination of DNA replication
appears to be normal in VprBP-depleted cells. We observed a
difference in the cell cycle profile due to loss of VprBP in
MEFs and HeLa cells that may be attributable to the intact p53
checkpoint pathway in MEFs. In HeLa cells, the most notice-
able defect in DNA replication caused by the loss of function
of VprBP is the substantial reduction of BrdU incorporation
during middle to late S phase of the cell cycle and an increase
in newly fired DNA replication origins (Fig. 4). These findings
provide a molecular basis—controlling the progression of
DNA replication—for the essential function of VprBP for cell
proliferation and embryo development.
VprBP shares some notable phenotypic similarities with the
Chk1 gene. In mice, the function of both VprBP and Chk1
genes are essential for MEF or ES cell viability and for early
embryonic development, with VprBP and Chk1 null embryos
dying before E7.5 and between E3.5 and E6.5, respectively
(Fig. 6) (24, 40). Codeletion of p53 did not significantly rescue
lethality of either VprBP (our unpublished observation) or
Chk1 null embryos (24). Both VprBP and Chk1 proteins bind
to chromatin in unperturbed cells (Fig. 5) (37), but neither
plays a major function in the assembly of prereplication com-
plexes or entry into the S phase. Instead, knocking down Chk1
or VprBP in otherwise unperturbed HeLa cells reduced the
rates of replication fork progression (28) and the rate of BrdU
incorporation (Fig. 4). As for Chk1-compromised cells (25),
HeLa cells after the silencing of VprBP also displayed in-
creased new origin firing (Fig. 4). We thus far have not de-
tected any role in DNA damage checkpoints for VprBP, unlike
Chk1, which is dissociated from chromatin and causes G2/M
cell cycle arrest following DNA damage. In UV-irradiated
cells, we did not detect any change of either the steady-state
level of VprBP or its chromatin association, nor did we detect
any effects of the silencing of VprBP on the increased chro-
matin binding of DDB1 and CUL4A (Fig. 5B) or on CDT1
degradation (our unpublished observation). Together, these
results indicate that VprBP is unlikely to play a major role in
DNA repair. While the detailed biochemical mechanism un-
derlying the function of VprBP in DNA replication is yet to be
determined, we favor a model whereby VprBP functions, in a
manner similar to Chk1, in the progression of DNA replication
during S phase, perhaps by either maintaining the stability of
forks or coordinating sequential firing of early and later origins
during an unperturbed S phase, as opposed to a function of
VprBP in suppressing dormant replication origins.
How does Vpr bind to VprBP to benefit HIV viral replica-
tion? Although not essential for HIV-1 replication in cell cul-
ture, the Vpr accessory protein has an important function in
lentivirus pathogenesis, as evidenced by its conservation in
HIV-1, HIV-2, and simian immunodeficiency virus and by the
attenuated progression of AIDS in rhesus monkeys infected
with simian immunodeficiency virus lacking Vpr and the very
similar accessory protein Vpx (12). How Vpr facilitates HIV
pathogenesis, however, remains unclear. Two consistent effects
on host cells upon ectopic expression of Vpr are its ability to
cause G2 cell cycle arrest (20, 33) and its ability to activate the
ATR-mediated DNA damage checkpoint pathway (34). Re-
cently, a number of studies concurrently reported that VprBP
is a major cellular binding partner of and is required for the G2
arrest caused by Vpr (3, 8, 17, 24, 35, 39, 42). Almost all of the
studies concluded that VprBP is required for Vpr-induced G2
cell cycle arrest based on the observation that Vpr ectopic
expression did not cause a G2 accumulation in cells with
VprBP knocked down. Our findings that the function of
VprBP is essential for progression through S phase suggest
that this conclusion needs to be viewed more cautiously. In
VprBP-silenced cells, we have found that nocodazole treat-
ment did not cause any appreciable G2 accumulation.
Our findings favor a model that Vpr, through its interaction
with VprBP, diverts the cellular chromosome replication ma-
chinery to facilitate viral replication. A consequence of this
diversion by Vpr, as observed with either knocking down or
deleting VprBP, would be reduced DNA replication and in-
creased firing of replication origins. Two lines of evidence
support this model. First, both VprBP (Fig. 5) and Vpr (23)
associate with chromatin, suggesting the possibility that Vpr
interacts with a chromatin-binding pool of VprBP. Second, we
have shown that the function of VprBP is essential for the
progression of DNA replication but not replication initiation.
This finding would suggest that Vpr is more likely to interact
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with VprBP to divert an ongoing chromosomal replication
activity toward viral replication rather than inducing G0 qui-
escent cells to enter the cell cycle. The challenging issue re-
mains to determine whether Vpr achieves this function by
increasing the activity of VprBP-DDB1-CUL4-ROC1 E3 li-
gase activity toward its normal substrate(s) or by hijacking the
ligase to target a different substrate(s).
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